How Hong Kong plays a central role in the biotech investment boom

  • HKEX listing reforms have led to IPOs from a broader range of companies, turning the city into Asia’s largest biotech fundraising hub
  • Hong Kong’s position in the Greater Bay Area enables companies to tap into vast pools of talent and funding in mainland China

Topic |   Hub for the future of health care